Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

BACKGROUND/AIM: Gemcitabine, dexamethasone and cisplatin (GDP) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobi...

Descripción completa

Detalles Bibliográficos
Autores principales: BATGİ, Hikmettullah, BAŞCI1, Semih, DAL1, Mehmet Sinan, KIZIL ÇAKAR, Merih, UNCU ULU, Bahar, YİĞENOĞLU, Tuğçe Nur, ÖZCAN, Nurgül, KILINÇ, Ali, MERDİN, Alparslan, YILDIZ, Jale, BAKIRTAŞ, Mehmet, ŞAHİN, Derya, DARÇIN, Tahir, İSKENDER, Dicle, BAYSAL, Nuran Ahu, ALTUNTAŞ, Fevzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203130/
https://www.ncbi.nlm.nih.gov/pubmed/33237657
http://dx.doi.org/10.3906/sag-2008-114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203130/
https://www.ncbi.nlm.nih.gov/pubmed/33237657
http://dx.doi.org/10.3906/sag-2008-114

Ejemplares similares